CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $423,054.66 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 9,973 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the sale, the chief executive officer now owns 180,890 shares of the company’s stock, valued at $7,673,353.80. This represents a 5.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Wednesday, February 19th, Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $42.12 on Friday. The stock’s 50 day moving average price is $43.06 and its 200 day moving average price is $45.58. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $75.91. The company has a market cap of $3.61 billion, a PE ratio of -9.64 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on CRSP. Morgan Stanley lifted their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Citigroup cut their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research report on Tuesday, February 18th. Evercore ISI raised CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $60.00 to $99.00 in a report on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Finally, Royal Bank of Canada lowered their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and an average target price of $73.11.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC boosted its stake in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. Capital International Investors grew its holdings in CRISPR Therapeutics by 10.3% in the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after purchasing an additional 816,789 shares during the last quarter. Baker BROS. Advisors LP increased its position in shares of CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after buying an additional 743,075 shares in the last quarter. Finally, State Street Corp raised its stake in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.